Optimizing Therapy for Endometrial Cancer: Recent Data Highlights

Dive into the evolving landscape of endometrial cancer, including rising incidence, classification, racial disparities, and emerging modalities, as discussed by experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD.

Explore the case of a 67-year-old patient with recurrent endometrial cancer, highlighting the importance of MMR testing, NGS, and emerging treatment options in today's landscape.

Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.

Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.

Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.

Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.